A-101 Solution

Phase 3Completed

1 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Seborrheic Keratosis

Conditions

Seborrheic Keratosis

Trial Timeline

Jan 1, 2016 → Oct 1, 2016

NCT ID

NCT02667275

About A-101 Solution

A-101 Solution is a phase 3 stage product being developed by Aclaris Therapeutics for Seborrheic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02667275. Target conditions include Seborrheic Keratosis.

What happened to similar drugs?

2 of 5 similar drugs in Seborrheic Keratosis were approved

Approved (2) Terminated (0) Active (3)

✅KetoconazoleGSK plcApproved

🔄Roflumilast Foam + Vehicle FoamArcutis BiotherapeuticsPhase 3

🔄A-101 SolutionAclaris TherapeuticsPhase 3

✅A-101 Topical SolutionAclaris TherapeuticsApproved

🔄A-101 SolutionAclaris TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02667275	Phase 3	Completed	Jan 1, 2016	Oct 1, 2016	Seborrheic Keratosis
NCT02667236	Phase 3	Completed	Jan 1, 2016	Oct 1, 2016	Seborrheic Keratosis
NCT02667288	Phase 3	Completed	Jan 1, 2016	Oct 1, 2016	Seborrheic Keratosis

Competing Products

15 competing products in Seborrheic Keratosis

See all competitors

Product	Company	Stage	Hype Score
Elidel + Ketoconazole Cream	Novartis	Phase 2	35
PF-07038124 + Placebo Ointment	Pfizer	Phase 2	27
Ketoconazole	GSK plc	Approved	43
Azelaic Acid 15% Gel + Inactive 15% gel base	Bayer	Phase 2	32
Ruxolitinib 1.5% Cream	Incyte	Phase 2	32
Roflumilast Foam 0.3% + Vehicle foam	Arcutis Biotherapeutics	Phase 2	29
Roflumilast Foam + Vehicle Foam	Arcutis Biotherapeutics	Phase 3	34
ARQ-154	Arcutis Biotherapeutics	Phase 2	29
A-101 Solution	Aclaris Therapeutics	Phase 3	30
A-101 Topical Solution	Aclaris Therapeutics	Approved	33
A-101	Aclaris Therapeutics	Phase 2	25
A-101 Solution	Aclaris Therapeutics	Phase 3	30
A-101	Aclaris Therapeutics	Phase 2	25
A-101 25% + A-101 32.5% + A-101 40% + A-101 Vehicle	Aclaris Therapeutics	Phase 1/2	22
A-101 Vehicle + A-101 (40) Topical Solution + A-101 (32.5) Topical Solution	Aclaris Therapeutics	Phase 2	25